JP2021512051A5 - - Google Patents
Info
- Publication number
- JP2021512051A5 JP2021512051A5 JP2020537529A JP2020537529A JP2021512051A5 JP 2021512051 A5 JP2021512051 A5 JP 2021512051A5 JP 2020537529 A JP2020537529 A JP 2020537529A JP 2020537529 A JP2020537529 A JP 2020537529A JP 2021512051 A5 JP2021512051 A5 JP 2021512051A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitors
- receptor
- modifiers
- pharmaceutical composition
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023146956A JP2023182599A (ja) | 2018-01-23 | 2023-09-11 | ペプチドｙｙ薬学的調剤物、組成物、および方法 |
| JP2025036312A JP2025093997A (ja) | 2018-01-23 | 2025-03-07 | ペプチドｙｙ薬学的調剤物、組成物、および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862620580P | 2018-01-23 | 2018-01-23 | |
| US62/620,580 | 2018-01-23 | ||
| US201862669191P | 2018-05-09 | 2018-05-09 | |
| US62/669,191 | 2018-05-09 | ||
| PCT/US2019/014720 WO2019147650A1 (en) | 2018-01-23 | 2019-01-23 | Peptide yy pharmaceutical formulations, compositions, and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023146956A Division JP2023182599A (ja) | 2018-01-23 | 2023-09-11 | ペプチドｙｙ薬学的調剤物、組成物、および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021512051A JP2021512051A (ja) | 2021-05-13 |
| JP2021512051A5 true JP2021512051A5 (https=) | 2022-01-27 |
Family
ID=67391725
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020537529A Pending JP2021512051A (ja) | 2018-01-23 | 2019-01-23 | ペプチドｙｙ薬学的調剤物、組成物、および方法 |
| JP2023146956A Pending JP2023182599A (ja) | 2018-01-23 | 2023-09-11 | ペプチドｙｙ薬学的調剤物、組成物、および方法 |
| JP2025036312A Pending JP2025093997A (ja) | 2018-01-23 | 2025-03-07 | ペプチドｙｙ薬学的調剤物、組成物、および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023146956A Pending JP2023182599A (ja) | 2018-01-23 | 2023-09-11 | ペプチドｙｙ薬学的調剤物、組成物、および方法 |
| JP2025036312A Pending JP2025093997A (ja) | 2018-01-23 | 2025-03-07 | ペプチドｙｙ薬学的調剤物、組成物、および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11911445B2 (https=) |
| EP (1) | EP3743092A4 (https=) |
| JP (3) | JP2021512051A (https=) |
| KR (1) | KR20200132852A (https=) |
| CN (1) | CN112074286A (https=) |
| AU (2) | AU2019211322A1 (https=) |
| BR (1) | BR112020014596A2 (https=) |
| CA (1) | CA3087733A1 (https=) |
| IL (1) | IL276169A (https=) |
| MX (1) | MX2020007410A (https=) |
| WO (1) | WO2019147650A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010090876A2 (en) | 2009-01-21 | 2010-08-12 | University Of Florida Research Foundation, Inc. | Satiation peptide administration |
| US11311633B2 (en) | 2016-04-16 | 2022-04-26 | University Of Florida Research Foundation, Incorporated | Satiation peptides for weight loss and altered taste sensitivity |
| WO2019147650A1 (en) | 2018-01-23 | 2019-08-01 | Gila Therapeutics, Inc. | Peptide yy pharmaceutical formulations, compositions, and methods |
| CA3124260C (en) * | 2018-12-21 | 2023-01-03 | Universite De Strasbourg | Peptides for treatment and prevention of diabetes and associated disorders |
| MX2021008661A (es) | 2019-01-18 | 2021-08-19 | Astrazeneca Ab | Inhibidores de la pcsk9 y metodos de uso de los mismos. |
| BR112021013807A2 (pt) | 2019-01-18 | 2021-11-30 | Astrazeneca Ab | Inibidores de pcsk9 e seus métodos de uso |
| CR20220206A (es) | 2019-11-11 | 2022-06-16 | Boehringer Ingelheim Int | Agonistas del receptor npy2 |
| US20230079395A1 (en) * | 2020-02-13 | 2023-03-16 | Ferrer Internacional, S.A. | Ophthalmic pharmaceutical composition and use thereof |
| JP7661478B2 (ja) | 2020-08-07 | 2025-04-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性ｎｐｙ２受容体アゴニスト |
| WO2022224061A1 (en) * | 2021-04-21 | 2022-10-27 | Societe Des Produits Nestle Sa | Methods of identifying modulators of receptors over-expressed in circumvallate taste papillae in animals such as cats, methods of using such modulators in food, and foods made by such methods |
| AU2022267568A1 (en) * | 2021-04-30 | 2023-11-16 | Innovent Biologics (Suzhou) Co., Ltd. | Oxm3 storage agent, oxm3 preparation, and preparation method |
| JP2024527528A (ja) * | 2021-06-24 | 2024-07-25 | ギラ セラピューティクス インコーポレイテッド | 満腹感を誘導する、及び代謝障害を治療するための方法及びキット |
| EP4299057A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4180060A1 (en) | 2021-11-15 | 2023-05-17 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| WO2023084118A1 (en) | 2021-11-15 | 2023-05-19 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| CN114306207A (zh) * | 2021-12-30 | 2022-04-12 | 电子科技大学 | 一种以棒棒糖为载体的口腔给药方法 |
| EP4299052A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and a permeation enhancer |
| EP4299071A1 (en) | 2022-07-01 | 2024-01-03 | Adocia | Compositions comprising a peptide or a protein and an acylated amino acid |
| US12171880B2 (en) * | 2022-09-08 | 2024-12-24 | Taiwan Mercury Medical Corporation | Metformin tablet for relieving pain and reducing inflammation and manufacturing method thereof |
| DE102024102935A1 (de) * | 2024-02-01 | 2025-08-07 | Briu Gmbh | Schmelztablette, insbesondere zur Verwendung als Nahrungsergänzungsmittel |
| WO2025208093A1 (en) * | 2024-03-28 | 2025-10-02 | Gila Therapeutics, Inc. | Compositions and methods for treating metabolic diseases with topical-lingual receptor agonists |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| US6558708B1 (en) | 1995-05-17 | 2003-05-06 | Cedars-Sinai Medical Center | Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia |
| US7745216B2 (en) | 1999-02-10 | 2010-06-29 | Curis, Inc. | Methods and reagents for treating glucose metabolic disorders |
| EP2123293A3 (en) | 2000-12-14 | 2010-09-08 | Amylin Pharmaceuticals, Inc. | Peptide YY and petide YY agonists for treatment of metabolic disorders |
| US7208186B2 (en) | 2001-09-18 | 2007-04-24 | Spi Pharma, Inc. | Chewing gum formulation and method of making the same |
| CN100350968C (zh) | 2001-09-24 | 2007-11-28 | 皇家创新有限公司 | 饮食行为的改进 |
| US20030198666A1 (en) | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| EP1474163A2 (en) | 2002-01-10 | 2004-11-10 | Imperial College Innovations Limited | Modification of feeding behavior |
| US20150283213A1 (en) | 2002-08-01 | 2015-10-08 | Mannkind Corporation | Method for treating hyperglycemia with glp-1 |
| US7166575B2 (en) | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
| US7229966B2 (en) | 2002-12-17 | 2007-06-12 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity |
| US7186692B2 (en) * | 2002-12-17 | 2007-03-06 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity |
| BR0316685A (pt) | 2002-12-17 | 2005-11-01 | Nastech Pharm Co | Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade |
| BRPI0411165A (pt) | 2003-05-14 | 2006-07-11 | Emisphere Tech Inc | composição farmacêutica, forma de unidade de dosagem e métodos para preparar seu uso |
| US20070149451A1 (en) | 2003-11-17 | 2007-06-28 | Holmes David G | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent |
| MXPA06013252A (es) | 2004-05-14 | 2007-02-28 | Emisphere Tech Inc | Compuestos y composiciones para suministrar agentes activos. |
| WO2005110467A1 (en) | 2004-05-18 | 2005-11-24 | Aditech Pharma Ab | A composition comprising pyy for the treatment of gastrointestinal disorders |
| US20080125360A1 (en) | 2004-05-18 | 2008-05-29 | Henrik Nilsson | Composition Comprising Pyy for the Treatment of Gastrointestinal Disorders |
| WO2006007412A2 (en) * | 2004-06-16 | 2006-01-19 | Nastech Pharmaceutical Company Inc. | Peptide yy formulations having increased stability and resistance to microbial agents |
| MX2007000510A (es) | 2004-07-12 | 2007-03-29 | Emisphere Tech Inc | Composiciones para suministrar peptido yy y agonistas de pyy. |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| JP2008514616A (ja) | 2004-09-24 | 2008-05-08 | メルク エンド カムパニー インコーポレーテッド | 肥満の治療のための組合せ療法 |
| US8283312B2 (en) | 2005-02-04 | 2012-10-09 | The Research Foundation Of State University Of New York | Compositions and methods for modulating body weight and treating obesity-related disorders |
| GB0504857D0 (en) | 2005-03-09 | 2005-04-13 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| WO2007008778A2 (en) | 2005-07-11 | 2007-01-18 | Nastech Pharmaceutical Company Inc. | Formulations for enhanced mucosal delivery of pyy |
| US20070104763A1 (en) | 2005-11-10 | 2007-05-10 | Navinta Llc | Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making |
| WO2008016729A1 (en) | 2006-08-04 | 2008-02-07 | Nastech Pharmaceutical Company Inc. | Compositions for intranasal delivery of human insulin and uses thereof |
| WO2008079342A2 (en) * | 2006-12-21 | 2008-07-03 | Mallinckrodt Inc. | Composition of and method for preparing orally disintegrating tablets |
| AU2007338751A1 (en) * | 2006-12-21 | 2008-07-03 | Mallinckrodt Inc. | Composition of and method for preparing orally disintegrating tablets containing a high dose of pharmaceutically active ingredients |
| CA2678646A1 (en) | 2007-03-05 | 2008-09-12 | Syracuse University | A conjugate of insulin and vitamin b12 for oral delivery |
| NZ580967A (en) | 2007-05-01 | 2012-04-27 | Cephalon Inc | Composition comprising a bile salt and an effervescent excipient component for transmucosal delivery of polypeptides |
| EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
| JP5580815B2 (ja) * | 2008-06-19 | 2014-08-27 | ユニバーシティ・オブ・ジ・ウィトウォーターズランド・ヨハネスブルク | 経粘膜デリバリーシステム |
| WO2010090876A2 (en) | 2009-01-21 | 2010-08-12 | University Of Florida Research Foundation, Inc. | Satiation peptide administration |
| AU2010212823B2 (en) | 2009-02-13 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
| KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| GB201001333D0 (en) | 2010-01-27 | 2010-03-17 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
| EP2387993B1 (en) | 2010-05-21 | 2012-11-07 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Orally disintegrating tablets of zolmitriptan and process for preparing the same |
| WO2011161161A1 (en) | 2010-06-24 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
| US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
| CN108892709A (zh) | 2011-05-18 | 2018-11-27 | 欧莫德里斯制药公司 | 改良的肽药物 |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| MX384232B (es) | 2013-03-14 | 2025-03-14 | Jerome J Schentag | Vesiculas colestosomicas para incorporacion de moleculas en quilomicrones. |
| AU2014235209B2 (en) * | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| SI3004155T1 (sl) | 2013-05-28 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Peptidna spojina |
| CA2978517A1 (en) * | 2014-03-04 | 2015-09-11 | Eastgate Pharmaceuticals Inc. | Pharmaceutical composition for transmucosal delivery and methods for treating diabetes in a subject in need thereof |
| WO2015177572A1 (en) | 2014-05-23 | 2015-11-26 | Imperial Innovations Limited | Peptide yy (pyy) analogues |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| US11311633B2 (en) | 2016-04-16 | 2022-04-26 | University Of Florida Research Foundation, Incorporated | Satiation peptides for weight loss and altered taste sensitivity |
| WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| JP6995042B2 (ja) | 2016-05-24 | 2022-02-04 | 武田薬品工業株式会社 | ペプチド化合物 |
| AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| CN107778336B (zh) | 2016-08-24 | 2022-09-27 | 宜昌东阳光长江药业股份有限公司 | 吡喃葡萄糖基衍生物的结晶形式 |
| WO2019139934A1 (en) | 2018-01-09 | 2019-07-18 | Gila Therapeutics, Inc. | Compositions and methods for treating metabolic diseases |
| WO2019147650A1 (en) | 2018-01-23 | 2019-08-01 | Gila Therapeutics, Inc. | Peptide yy pharmaceutical formulations, compositions, and methods |
-
2019
- 2019-01-23 WO PCT/US2019/014720 patent/WO2019147650A1/en not_active Ceased
- 2019-01-23 CA CA3087733A patent/CA3087733A1/en active Pending
- 2019-01-23 BR BR112020014596-3A patent/BR112020014596A2/pt unknown
- 2019-01-23 EP EP19744391.4A patent/EP3743092A4/en active Pending
- 2019-01-23 CN CN201980013534.9A patent/CN112074286A/zh active Pending
- 2019-01-23 JP JP2020537529A patent/JP2021512051A/ja active Pending
- 2019-01-23 KR KR1020207023953A patent/KR20200132852A/ko not_active Withdrawn
- 2019-01-23 MX MX2020007410A patent/MX2020007410A/es unknown
- 2019-01-23 US US16/255,105 patent/US11911445B2/en active Active
- 2019-01-23 AU AU2019211322A patent/AU2019211322A1/en not_active Abandoned
-
2020
- 2020-07-20 IL IL276169A patent/IL276169A/en unknown
-
2021
- 2021-06-01 US US17/335,753 patent/US20210308223A1/en not_active Abandoned
- 2021-06-01 US US17/335,610 patent/US20220143146A1/en not_active Abandoned
-
2023
- 2023-09-11 JP JP2023146956A patent/JP2023182599A/ja active Pending
-
2024
- 2024-12-23 US US18/999,019 patent/US20250121033A1/en active Pending
-
2025
- 2025-03-07 JP JP2025036312A patent/JP2025093997A/ja active Pending
- 2025-04-17 AU AU2025202747A patent/AU2025202747A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512051A5 (https=) | ||
| US11382957B2 (en) | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid | |
| AU2020202573B2 (en) | Use of long-acting GLP-1 peptides | |
| JP5918539B2 (ja) | Ｇｌｐ−１を用いる高血糖症の治療方法 | |
| ES2547529T3 (es) | Formulación en polvo seco inhalable que comprende GLP-1 para usar en el tratamiento de la hiperglucemia y diabetes por administración pulmonar | |
| US8921311B2 (en) | Method for treating hyperglycemia | |
| TWI623320B (zh) | 用於治療代謝症候群之醫藥組成物 | |
| US20150283213A1 (en) | Method for treating hyperglycemia with glp-1 | |
| Jones et al. | Islet function and insulin secretion | |
| JP2015526523A (ja) | 高血糖症の治療のための方法および組成物 | |
| JP2019524831A5 (https=) | ||
| JP2018501276A5 (https=) | ||
| US20060063719A1 (en) | Methods for treating diabetes | |
| Holst | Incretin therapy for diabetes mellitus type 2 | |
| US20110288001A1 (en) | Biologically active proteins activatable by peptidase | |
| US11304992B2 (en) | Inhalable dry powder pharmaceutical composition | |
| JP2024509829A (ja) | Ｇｌｐ－１受容体作動薬を経口投与するための医薬組成物 | |
| Bavec | Mono-ADP-ribosyltransferase as a potential pharmacological drug target in the GLP-1 based therapy of obesity and diabetes mellitus type 2. | |
| Abhay et al. | Pharmacotherapy Of Type 2 Diabetes–The Future | |
| Erol | Neural pathways and neuropeptides mediate the therapeutic actions of DPP IV inhibitors in type-2 diabetes |